Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial

American Heart Journal

Volumn 174, Issue , 2016, Pages 95-102

  Gargiulo, Giuseppe ^a,b   Costa, Francesco ^c,d   Ariotti, Sara ^a   Biscaglia, Simone ^e   Campo, Gianluca ^e   Esposito, Giovanni ^b   Leonardi, Sergio ^f   Vranckx, Pascal ^g   Windecker, Stephan ^a   Valgimigli, Marco ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g Hartcentrum Hasselt ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CREATININE; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY STENTING; CREATININE CLEARANCE; CRUSADE BLEEDING SCORE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; GASTROESOPHAGEAL REFLUX; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONARY BLOOD VESSEL; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FOLLOW UP; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; INTIMA; MIDDLE AGED; MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; PATHOLOGY; STENT; TIME FACTOR;

ADMINISTRATION, ORAL; AGED; ASPIRIN; CORONARY VESSELS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 84958787223     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.01.015     Document Type: Article

References (24)

1. M. Valgimigli, G. Campo, M. Monti, and et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
2. M. Valgimigli, F. Costa, R. Byrne, and et al. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey EuroIntervention 11 2015 68 74
3. E.P. Navarese, F. Andreotti, V. Schulze, and et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials BMJ 350 2015 h1618 10.1136/bmj.h1618
4. K.C. Lai, S.K. Lam, K.M. Chu, and et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use N Engl J Med 346 2002 2033 2038
5. Q.P. Gao, Y. Sun, Y.X. Sun, and et al. Early use of omeprazole benefits patients with acute myocardial infarction J Thromb Thrombolysis 28 2009 282 287
6. P.I. Hsu, K.H. Lai, and C.P. Liu Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis Gastroenterology 140 2011 791 798
7. F.H. Ng, P. Tunggal, W.M. Chu, and et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction Am J Gastroenterol 107 2012 389 396
8. D.S. Small, N.A. Farid, C.D. Payne, and et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel J Clin Pharmacol 48 2008 475 484
9. D. Sibbing, T. Morath, J. Stegherr, and et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 2009 714 719
10. M. Gilard, B. Arnaud, J.C. Cornily, and et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
11. M.L. O'Donoghue, E. Braunwald, E.M. Antman, and et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
12. U.S. Food and Drug Administration Public health advisory: updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC) 2010
13. European Medicines Agency Public statement on possible interaction between clopidogrel and proton pump inhibitors 2010
14. C. Melloni, J.B. Washam, W.S. Jones, and et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review Circ Cardiovasc Qual Outcomes 8 2015 47 55
15. R.N. Cardoso, A.M. Benjo, J.J. DiNicolantonio, and et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis Open Heart 2 2015 e000248 10.1136/openhrt-2015-000248
16. D.L. Bhatt, B.L. Cryer, C.F. Contant, and et al. Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
17. S.P. Dunn, S.R. Steinhubl, D. Bauer, and et al. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials J Am Heart Assoc 2 2013 e004564 10.1161/JAHA.112.004564
18. S.G. Goodman, R. Clare, K.S. Pieper, and et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial Circulation 125 2012 978 986
19. K.J. Harjai, C. Shenoy, P. Orshaw, and et al. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators Circ Cardiovasc Interv 4 2011 162 170
20. N.H. Shah, P. LePendu, A. Bauer-Mehren, and et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population PLoS One 10 2015 e0124653 10.1371/journal.pone.0124653
21. H. Aihara, A. Sato, N. Takeyasu, and et al. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry Catheter Cardiovasc Interv 80 2012 556 563
22. T. Burkard, C.A. Kaiser, H. Brunner-La Rocca, and et al. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial J Int Med 271 2012 257 263
23. G. Weisz, N.R. Smilowitz, A.J. Kirtane, and et al. Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients: the ADAPT-DES study Circ Cardiovasc Interv 8 2015 10.1161/CIRCINTERVENTIONS.114.001952
24. M. Valgimigli, G. Campo, G. Percoco, and et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Am Heart J 160 2010 804 811